Madrigal Pharmaceuticals, Inc. reports results for the quarter ended September 30 - Earnings Summary

What happened

Madrigal Pharmaceuticals reported quarterly adjusted earnings of $1.83 per share, beating analyst expectations of a 91-cent loss. Revenue rose 50.1% to $431.27 million, above the $404.26 million expected, and net income was $55.44 million.

Confirmed

Global impact / market context

A swing from a prior-year loss to a $1.83 profit per share shows sales now cover costs, which matters because a biotech that funds itself from product revenue relies less on borrowed money or new share sales.

Analyst inference

Despite the profit beat, the stock fell 14.4% this quarter and 26.0% this year. Analysts still rate it buy with a $670 median price target, 35.6% above the $431.16 last close, showing a gap between results and share performance.

Analyst inference

What to watch

1. Analyst estimates for earnings fell about 7.3% over the last three months, while no negative revisions occurred in the past 30 days, which means expectations stabilized recently. Confirmed
2. Watch whether the company can keep revenue growing fast enough to sustain profit, since one quarter of net income does not confirm a lasting trend. Proposed
3. Track whether the wide gap between the $670 median price target and the $431.16 last close narrows, as it signals how investors weigh profit against the stock's weak year-to-date performance. Analyst inference

Evidence

• Original source link unavailable